Pharmaust - Media & News, page-161

Well how many millions of dollars did the old board waste by not progressing with great data, with shareholders backing them all the way.
Did they do some good work well yes they did but a lot of that good work was let slide.
Has the new board delivered anything other than what was already on the drawing board, in my opinion no they havent.
Have you seen any real change in direction since the new board took over, again in my opinion the answer is no, a lot of talking but little to show for it.
It's over 12 months ago that the phase 1 trial finished and still we wait for the phase 2 to start.
How much long do shareholders have to wait, how much longer do mnd patients have to wait, if mpl is as good as we are lead to believe then every effort needs to be taken to get the phase 2 going or even open g up the extended trial to more patients.
Time is money, time is patients missing out on a possible treatment